ANGELALIGN (06699) announced its 2025 interim results, reporting revenue of $161.4 million, an increase of 33.1% year-on-year. Gross profit reached approximately $100 million, up 32.9% year-on-year. Adjusted net profit was $19.5 million, representing an 84.8% increase year-on-year. Profit attributable to owners reached $14.643 million, surging 362.65% year-on-year. Earnings per share were $0.09, with a special interim dividend of HK$0.46 per share.

In the first half of 2025, the company achieved solid performance results. Rising case volumes, efficient operations of medical design centers and clear aligner manufacturing facilities collectively drove year-on-year growth in revenue, gross profit, and operating profit. The company's earnings performance during the reporting period also benefited from strict cost control measures implemented in anticipation of a more challenging tariff environment, including: temporary suspension of recruitment in sales, marketing, clinical support, and customer service across certain regions, as well as delayed operations of medical design centers and manufacturing facilities outside mainland China.

During the reporting period, case volumes in global markets outside mainland China (including AngelAligner brand aligners, Aditek brand aligners, and customized aligners for simple cases of key strategic clients) grew rapidly, reflecting the group's initial success in entering new markets and benefiting from low-hanging fruit. The company expanded its market coverage outside mainland China through high-quality medical design support, stable delivery, combined with continuous education and training led by key opinion leaders (KOLs) and customized aligners for simple cases of key strategic clients.

During the reporting period, the company completed approximately 117,200 clear aligner cases in global markets outside mainland China (including AngelAligner brand aligners, Aditek brand aligners, and customized aligners for simple cases of key strategic clients), representing a 103.5% year-on-year increase. This reflects both the company's relatively low business base last year and the initial success achieved by entering new markets previously unexplored and benefiting from low-hanging fruit. Looking ahead, the company expects to increase investment in sales, marketing, clinical support, and customer service to establish a more solid and sustainable influence.